Panitumumab Suppliers & Bulk Manufacturers
Available Forms: Solution for Infusion
Available Strengths: 100 mg/5 mL
Reference Brands: Vectibix (USA/LATAM/India)
Category:
Oncology Cancer Care
Panitumumab is available in Solution for Infusion
and strengths such as 100 mg/5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Panitumumab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Panitumumab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Panitumumab is a targeted anticancer medicine used in the treatment of metastatic colorectal cancer. It is a fully human monoclonal antibody that works as an epidermal growth factor receptor (EGFR) antagonist. EGFR is a protein found on the surface of some cancer cells that helps them grow, divide, and spread. By binding specifically to this receptor, panitumumab blocks the signals that promote tumor cell growth and survival. This targeted action helps slow or stop the progression of cancer in certain patients.
Panitumumab is commonly used as a single-agent therapy in patients with metastatic colorectal carcinoma whose disease has progressed after standard chemotherapy treatments such as fluoropyrimidine, oxaliplatin, and irinotecan. It is particularly effective in patients whose tumors have RAS wild-type status, as this genetic profile allows the drug to work more effectively against EGFR-driven tumor growth.
The medicine is administered as an intravenous infusion under medical supervision, usually in specialized oncology treatment settings. As a biologic therapy designed to target specific cancer pathways, panitumumab plays an important role in modern precision oncology, helping improve treatment outcomes and disease management for patients with advanced colorectal cancer.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing